Hilltop National Bank Decreases Holdings in McKesson Co. (NYSE:MCK)

Hilltop National Bank lowered its position in McKesson Co. (NYSE:MCK - Free Report) by 58.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,584 shares of the company's stock after selling 2,241 shares during the quarter. Hilltop National Bank's holdings in McKesson were worth $903,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of MCK. Wolff Wiese Magana LLC increased its holdings in McKesson by 742.9% during the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock valued at $29,000 after buying an additional 52 shares during the period. MidAtlantic Capital Management Inc. purchased a new position in shares of McKesson in the 3rd quarter valued at $29,000. RPg Family Wealth Advisory LLC bought a new position in shares of McKesson in the 3rd quarter worth $31,000. ORG Wealth Partners LLC purchased a new stake in shares of McKesson during the 3rd quarter worth $40,000. Finally, Centennial Bank AR bought a new stake in McKesson during the second quarter valued at about $53,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Price Performance

MCK traded down $8.53 during trading on Friday, reaching $581.73. 597,052 shares of the company's stock were exchanged, compared to its average volume of 614,970. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51. The company's fifty day simple moving average is $591.44 and its 200-day simple moving average is $561.65. The stock has a market capitalization of $73.84 billion, a P/E ratio of 30.13, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.88 by $0.19. The company had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The firm's quarterly revenue was up 21.3% on a year-over-year basis. During the same period in the previous year, the firm posted $6.23 earnings per share. Equities analysts forecast that McKesson Co. will post 32.73 EPS for the current year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date was Monday, December 2nd. McKesson's payout ratio is presently 14.71%.

Insiders Place Their Bets

In other news, EVP Leann B. Smith sold 579 shares of the firm's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total transaction of $331,645.41. Following the sale, the executive vice president now directly owns 864 shares in the company, valued at $494,890.56. This trade represents a 40.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.11% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on MCK. Evercore ISI increased their price target on shares of McKesson from $560.00 to $680.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their target price on shares of McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a research note on Friday, December 13th. Deutsche Bank Aktiengesellschaft cut their price target on shares of McKesson from $623.00 to $579.00 and set a "buy" rating on the stock in a report on Wednesday, September 25th. Citigroup decreased their price objective on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a report on Friday. Finally, Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and upped their target price for the company from $531.00 to $688.00 in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.